# Landscapes of HLA Mismatching in Contemporary Unrelated Haematopoietic Cell Transplantation

**Authors:** Esteban Arrieta‐Bolaños, Edouard F. Bonneville, Pietro Crivello, Tobias Gedde‐Dahl, Régis Peffault de Latour, Urpu Salmenniemi, Nicolaus Kröger, Ibrahim Yakoub‐Agha, Marco Zecca, Goda Choi, Charles Crawley, Eleni Tholouli, Valérie Dubois, Juha Peräsaari, Lotte Wieten, Steven G. E. Marsh, Mats Bengtsson, Jorinde D. Hoogenboom, Jürgen Kuball, Florent Malard, Annalisa Ruggeri, Katharina Fleischhauer

PMC · DOI: 10.1111/tan.70637 · 2026-03-11

## TL;DR

This study analyzes HLA mismatch patterns in unrelated blood cell transplants, showing how mismatch frequencies have changed over time and how they affect patient outcomes.

## Contribution

The first large-scale analysis of real-world HLA mismatch frequencies in contemporary unrelated hematopoietic cell transplantation.

## Key findings

- 25% of transplants involved mismatches at one or more HLA loci, with a higher proportion in transplants using post-transplantation cyclophosphamide.
- Single class I mismatches were three times more common than class II mismatches across all transplant eras.
- Matching for HLA-DPB1 increased from 15% pre-2011 to 31% in 2021–2022.

## Abstract

Haematopoietic cell transplantation (HCT) with HLA‐mismatched unrelated donors (MMUD) offers access to curative therapy for patients lacking well‐matched donors. Accumulating evidence suggests that functional matching among allele‐mismatched pairs can significantly influence patient outcomes. Therefore, real‐world data on mismatch frequencies in MMUD‐HCT could provide fundamental information for the assessment of patient risks and donor selection strategies. Here, we analysed HLA matching in 28,376 first unrelated transplants reported to the EBMT Registry with available 6‐locus high‐resolution typing. Mismatches at each locus were quantified and characterised at the allelic, antigenic and functional (antigen‐recognition domain, peptide‐binding motif) levels. 25% of the transplants were performed across one (9/10; n = 6053) or more (< 9/10; n = 1013) high‐resolution mismatches at the five main HLA loci, a proportion that was markedly higher (43.9%) among transplants performed with post‐transplantation cyclophosphamide (PTCy). Median time from diagnosis to transplant was longer for MMUD compared to 10/10 transplants, but this difference decreased over time (14.9 vs. 11.3 months pre‐2011, p = 0.003; 8.1 vs. 7.4 months 2021–2022, p = 0.016). Across transplant eras, single class I mismatches were three times more common than class II mismatches. Conversely, matching for HLA‐DPB1 increased from 15% pre‐2011 to 31% in 2021–2022. The landscapes of allelic mismatches differed markedly between HLA loci. For class II, skewed distributions dominated by frequent combinations result in significantly higher frequencies of functional matching compared to class I in both PTCy and non‐PTCy pairs. Our study constitutes the first large‐scale characterisation of real‐world HLA mismatch frequencies in contemporary unrelated HCT, bearing implications for future clinical outcome studies.

## Linked entities

- **Genes:** HLA-DPB1 (major histocompatibility complex, class II, DP beta 1) [NCBI Gene 3115]
- **Chemicals:** cyclophosphamide (PubChem CID 2907)

## Full-text entities

- **Genes:** HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, ADI1 (acireductone dioxygenase 1) [NCBI Gene 55256] {aka APL1, ARD, ARD', Fe-ARD, HMFT1638, MTCBP1}, HLA-DPB1 (major histocompatibility complex, class II, DP beta 1) [NCBI Gene 3115] {aka DPB1, HLA-DP, HLA-DP1B, HLA-DPB}, HLA-B (major histocompatibility complex, class I, B) [NCBI Gene 3106] {aka AS, B-4901, HLAB}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, HLA-DQB1 (major histocompatibility complex, class II, DQ beta 1) [NCBI Gene 3119] {aka CELIAC1, HLA-DQB, IDDM1}, HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123] {aka DRB1, HLA-DR1B, HLA-DRB, SS1}
- **Diseases:** haematological malignancies (MESH:D009369), haematological and immunological diseases (MESH:D007154), ALL (MESH:D054198), acute leukaemias (MESH:D054218), GvHD (MESH:D006086), MMUD (MESH:C536928), chronic leukaemias (MESH:D015451), myelodysplastic or myeloproliferative neoplasms (MESH:D054437), hematologic malignancies (MESH:D019337), MDS (MESH:D009190), inherited disorders (MESH:D030342), AML (MESH:D015470), plasma cell disorders (MESH:D007952), bone marrow failure syndromes (MESH:D000080983), chronic myelomonocytic leukaemia (MESH:D015477), Hodgkin and non-Hodgkin lymphoma (MESH:D008228)
- **Chemicals:** TCE (MESH:D014241), MMF (MESH:D009173), PTCy (-), CsA (MESH:D016572), alemtuzumab (MESH:D000074323), tacrolimus (MESH:D016559), cyclophosphamide (MESH:D003520), MTX (MESH:D008727)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs9277534, G/A

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12978212/full.md

---
Source: https://tomesphere.com/paper/PMC12978212